The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become ...
Prognostic value of baseline immune suppressive biomarkers to select non-small cell lung cancer (NSCLC) patients (pts) likely to benefit from the plinabulin/docetaxel (Plin/Doc) combination. This is ...
Beveridge, now with Avalere Health, addressed the importance of clinical pathways in selecting therapies in non-small cell lung cancer (NSCLC) and the emergence of options for EGFR Exon 20 Insertion+ ...
Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ). This is an ASCO Meeting ...
Edward Arrowsmith, MD, MPH, medical director for clinical pathways for OneOncology, discussed treatment challenges in EGFR Exon 20 insertion+ non-small cell lung cancer (NSCLC) and best practices in ...
Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming second-line NSCLC treatment post-TKI failure. The HARMONi trial showed ivonescimab ...
Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace AstraZeneca’s Tagrisso as the new standard of care in first-line ...
Identifying population-based eGFR distributions may help to identify patients at risk for developing chronic kidney disease earlier, according to study data published in Kidney International. More ...
The FDA has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneous, chemo-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results